Biopharma Veteran Mark Altmeyer to Steer ReproNovo's Fertility Push

LAUSANNE, SWITZERLAND – March 20, 2026 – Clinical-stage biopharmaceutical company ReproNovo SA has made a significant strategic move, appointing Mark Altmeyer, a highly regarded biopharma executive with a formidable track record in commercialization and M&A, as the new Chairman of its Board of Directors. The appointment signals a clear intent to accelerate the company’s mission of addressing critical gaps in fertility and women's health, pairing its promising clinical assets with seasoned leadership capable of navigating the path to market.

An Architect of Billion-Dollar Exits and Blockbuster Drugs

Mark Altmeyer is not just another name on a board roster; he is a proven architect of value in the biopharmaceutical industry. His more than 35-year career is punctuated by leadership roles that have transformed high-growth biotech companies and steered blockbuster drugs to market dominance.

Most notably, Altmeyer was the Founder and CEO of Arvelle Therapeutics. Within just two years, he orchestrated the company's transatlantic expansion, secured over $200 million in financing, and culminated his tenure with the company's acquisition by Angelini Pharma in a deal valued at nearly $1 billion. This rapid and lucrative exit cemented his reputation as a leader who can build, scale, and deliver significant returns.

His earlier career includes pivotal roles at Bristol Myers Squibb and Otsuka. At Otsuka, he was a key figure behind the launch and meteoric rise of Abilify, an antipsychotic medication. Under his commercial leadership, Abilify became the top-selling pharmaceutical product in the United States in 2013, with revenues soaring past $7 billion. This experience demonstrates a deep understanding of complex commercialization strategies and market expansion on a global scale.

“Mark is distinguished by a rare blend of board-level leadership and operational excellence covering the full biopharma lifecycle, combining entrepreneurial drive with disciplined governance and a strategic, stakeholder-oriented mindset,” said Jean Marie Duvall, Chief Executive Officer and Co-Founder of ReproNovo, in a statement. “He has successfully guided companies through critical development and strategic inflection points, capabilities that will be highly valuable as we globally advance RPN-001 and RPN-002 across four indications in fertility and women’s health.”

Altmeyer's board experience is equally extensive. He currently serves as Chairman of AM-Pharma and Calluna Pharma and previously held an Independent Director role at Myovant Sciences, which was later acquired by Sumitomo Pharma in a transaction valued at approximately $3 billion. This pattern of guiding companies toward successful strategic outcomes is a clear asset for ReproNovo.

Targeting Vast, Underserved Markets in Reproductive Health

ReproNovo is positioning itself to become a leader in therapeutic areas that have historically seen limited innovation despite affecting millions worldwide. The company’s clinical pipeline is focused on two highly differentiated compounds addressing significant unmet needs in male and female fertility and women’s health.

The company's lead asset for male infertility is RPN-001 (leflutrozole), an aromatase inhibitor currently in a U.S. Phase 2 trial. It is designed to treat men with low sperm count and low testosterone by rebalancing key hormones to enhance testicular function and sperm production. With male factors contributing to roughly 30% of all infertility cases and the global male infertility market projected to exceed $6 billion by 2030, a successful therapy could capture a substantial market.

Its second asset, RPN-002 (nolasiban), is a first-in-class oxytocin receptor antagonist being developed for two separate indications. The first is to improve embryo implantation success rates for women undergoing in-vitro fertilization (IVF), a procedure central to the multi-billion dollar fertility services market. By reducing uterine contractions and increasing blood flow, nolasiban aims to make the uterus more receptive to an embryo. The second indication is for the management of adenomyosis, a painful uterine condition affecting up to 30% of women with uterine disorders. The adenomyosis treatment market, while smaller, is growing rapidly due to increased awareness and diagnosis, creating an opportunity for a novel, non-invasive therapy.

"ReproNovo is addressing critical therapeutic gaps in areas that have seen limited innovation, despite these being really large markets," Altmeyer commented on his appointment. "I look forward to working with the Board and management team to maximize these highly differentiated products, create value and ultimately bring these products to patients."

The Strategic Playbook: Blending Science, Capital, and Leadership

The appointment of Mark Altmeyer is a classic move from the strategic playbook of successful venture-backed biotechs. It represents the crucial moment when a company with promising science and solid financial footing recruits top-tier commercial leadership to prepare for its next phase of growth.

ReproNovo is well-capitalized, having recently closed a $65 million Series A financing round. The round was led by prominent life sciences investor Jeito Capital, with strong participation from BNP Paribas Asset Management Alts, founding investor M Ventures, Ysios Capital, and ALSA Ventures. This funding provides the company with a runway into 2027 to advance both of its lead compounds through pivotal Phase 2 trials.

Bringing Altmeyer on board now is a deliberate strategy to de-risk the path forward. His expertise is vital for shaping late-stage clinical trial design with a commercial endpoint in mind, navigating complex global regulatory pathways, and building the framework for a successful product launch. Furthermore, his extensive M&A experience makes him an invaluable guide for evaluating potential strategic partnerships, licensing deals, or an eventual sale of the company—all potential avenues for maximizing investor returns and bringing therapies to patients.

This move reflects a broader industry trend where emerging biopharma companies are increasingly recognizing that scientific innovation alone is not enough. Success requires a trifecta of cutting-edge science, robust financial backing, and experienced leadership with the commercial acumen to translate clinical data into a marketable product. By adding Altmeyer as Chairman, ReproNovo has powerfully reinforced the third leg of this stool, signaling to investors, potential partners, and the broader market that it is building a company not just for clinical development, but for commercial success. His leadership will be instrumental as the company works to deliver on the promise held within its pipeline, potentially transforming the standard of care for infertility and women's health conditions.